MIAS Pharma Limited
Pierre-Henri Baviera is an accomplished executive with extensive experience in leadership roles across various sectors. Currently serving as the Chief Executive Officer at MIAS Pharma Limited since September 2022, Baviera previously held the same position at Derilinx and Presidion, where responsibilities included developing and executing growth strategies with full P&L accountability. Notable achievements include transforming Presidion from a UK and Ireland-based advanced analytics software resell business to a pan-European advanced analytics solution provider. Earlier career experience includes roles at Pathfinder Consulting, PA Consulting, Cap Gemini Ernst and Young, and H3 Technology, focusing on technology, data analytics, and management consulting. Pierre-Henri Baviera holds an MBA from University College Dublin and degrees in Electrical and Computer Engineering and Maths and Physics from CentraleSupélec and Paris-Sud University, respectively.
This person is not in any teams
This person is not in any offices
MIAS Pharma Limited
MIAS Pharma Limited is a company setup to facilitate pharmaceutical companies to import human medicinal product in to the European Market. As your European partner we can provide contract services which will enable you to import and batch release product into Europe in a compliant manner. MIAS Pharma Limited holds two MIAs (Manufacturing and Importation Authorisations) to cover medicinal products for human use in EU/EEA: 1. MIA for Investigational Medicinal Products (IMPs) 2. MIA for Commercial Products MIAS Pharma can also provide oversight of: 1. European Qualified Person (QP) services 2. Regulatory compliance of manufacturing activities 3. Regulatory compliance of Analytical Testing and Retesting 4. Regulatory compliance of Repackaging / Relabelling services 5. Regulatory compliance of Shipment and Transportation activities 6. Compliance with responsibilities as a Market Authorisation Holder (MAH)